Floatz logo

Enzalutamide

Anal Neoplasm

MacroGenicsSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Anal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jessa Hospital
Phase 4BB
v503
Merck Sharp & Dohme LLC
Phase 3BB
Capecitabine
Blokhin's Russian Cancer Research Center
Phase 3B
MITOMYCINS
Blokhin's Russian Cancer Research Center
Phase 3B
Vgx-3100
Inovio Pharmaceuticals
Phase 2B

View all 14 →

Same molecule, other indications

Enzalutamide is also rated in:

Metastatic Castration Resistant Prostate CancerDormant
BBB
Indicative ·
77 / 100
View asset →
prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
castration-resistant prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →